Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party

On behalf of the Korean Multiple Myeloma Working Party

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Bendamustine may be a potential treatment option for patients with myeloma, but little is known about the utility of bendamustine as a salvage treatment, especially in Asian patients. Methods We performed a multicenter retrospective study of patients with relapsed or refractory myeloma who received bendamustine and prednisone. Results The records of 65 heavily pre-treated patients, who had undergone bortezomib and lenalidomide treatment (median number of previous treatments: 5), were analyzed. The median time from diagnosis to bendamustine treatment was 3.8 years, and the median patient age was 63 years (range, 38-77 yr). The responses to the last treatment before bendamustine were refractory disease (N=52, 80%) or disease progression from partial response (N=13, 20%). Twenty-three patients responded to the treatment, with an overall response rate of 35% (23/65), and the median number of bendamustine treatment cycles was two (range, 1-5 cycles). The median overall survival after bendamustine treatment was 5.5 months and the overall survival rate in responders to bendamustine was significantly better than that in non-responders (P=0.036). Conclusion Bendamustine may be a potential salvage treatment to extend survival in a select group of heavily pre-treated patients with relapsed or refractory myeloma.

Original languageEnglish
Pages (from-to)193-199
Number of pages7
JournalBlood Research
Volume51
Issue number3
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Multiple Myeloma
Salvage Therapy
Therapeutics
Bendamustine Hydrochloride
Survival
Prednisone
Multicenter Studies
Disease Progression
Survival Rate
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

@article{48f03fa397114788af4e30f17758a277,
title = "Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party",
abstract = "Background Bendamustine may be a potential treatment option for patients with myeloma, but little is known about the utility of bendamustine as a salvage treatment, especially in Asian patients. Methods We performed a multicenter retrospective study of patients with relapsed or refractory myeloma who received bendamustine and prednisone. Results The records of 65 heavily pre-treated patients, who had undergone bortezomib and lenalidomide treatment (median number of previous treatments: 5), were analyzed. The median time from diagnosis to bendamustine treatment was 3.8 years, and the median patient age was 63 years (range, 38-77 yr). The responses to the last treatment before bendamustine were refractory disease (N=52, 80{\%}) or disease progression from partial response (N=13, 20{\%}). Twenty-three patients responded to the treatment, with an overall response rate of 35{\%} (23/65), and the median number of bendamustine treatment cycles was two (range, 1-5 cycles). The median overall survival after bendamustine treatment was 5.5 months and the overall survival rate in responders to bendamustine was significantly better than that in non-responders (P=0.036). Conclusion Bendamustine may be a potential salvage treatment to extend survival in a select group of heavily pre-treated patients with relapsed or refractory myeloma.",
author = "{On behalf of the Korean Multiple Myeloma Working Party} and Kim, {Seok Jin} and Bang, {Soo Mee} and Choi, {Yoon Seok} and Jo, {Deog Yeon} and Jinseok Kim and Hyewon Lee and Eom, {Hyeon Seok} and Yoon, {Dok Hyun} and Cheolwon Suh and Lee, {Je Jung} and Junshik Hong and Lee, {Jae Hoon} and Youngil Koh and Kihyun Kim and Yoon, {Sung Soo} and Min, {Chang Ki}",
year = "2016",
month = "1",
day = "1",
doi = "10.5045/br.2016.51.3.193",
language = "English",
volume = "51",
pages = "193--199",
journal = "Blood Research",
issn = "2287-979X",
publisher = "Korean Society of Hematology",
number = "3",

}

Bendamustine in heavily pre-treated multiple myeloma patients : Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. / On behalf of the Korean Multiple Myeloma Working Party.

In: Blood Research, Vol. 51, No. 3, 01.01.2016, p. 193-199.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bendamustine in heavily pre-treated multiple myeloma patients

T2 - Results of a retrospective analysis from the Korean Multiple Myeloma Working Party

AU - On behalf of the Korean Multiple Myeloma Working Party

AU - Kim, Seok Jin

AU - Bang, Soo Mee

AU - Choi, Yoon Seok

AU - Jo, Deog Yeon

AU - Kim, Jinseok

AU - Lee, Hyewon

AU - Eom, Hyeon Seok

AU - Yoon, Dok Hyun

AU - Suh, Cheolwon

AU - Lee, Je Jung

AU - Hong, Junshik

AU - Lee, Jae Hoon

AU - Koh, Youngil

AU - Kim, Kihyun

AU - Yoon, Sung Soo

AU - Min, Chang Ki

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background Bendamustine may be a potential treatment option for patients with myeloma, but little is known about the utility of bendamustine as a salvage treatment, especially in Asian patients. Methods We performed a multicenter retrospective study of patients with relapsed or refractory myeloma who received bendamustine and prednisone. Results The records of 65 heavily pre-treated patients, who had undergone bortezomib and lenalidomide treatment (median number of previous treatments: 5), were analyzed. The median time from diagnosis to bendamustine treatment was 3.8 years, and the median patient age was 63 years (range, 38-77 yr). The responses to the last treatment before bendamustine were refractory disease (N=52, 80%) or disease progression from partial response (N=13, 20%). Twenty-three patients responded to the treatment, with an overall response rate of 35% (23/65), and the median number of bendamustine treatment cycles was two (range, 1-5 cycles). The median overall survival after bendamustine treatment was 5.5 months and the overall survival rate in responders to bendamustine was significantly better than that in non-responders (P=0.036). Conclusion Bendamustine may be a potential salvage treatment to extend survival in a select group of heavily pre-treated patients with relapsed or refractory myeloma.

AB - Background Bendamustine may be a potential treatment option for patients with myeloma, but little is known about the utility of bendamustine as a salvage treatment, especially in Asian patients. Methods We performed a multicenter retrospective study of patients with relapsed or refractory myeloma who received bendamustine and prednisone. Results The records of 65 heavily pre-treated patients, who had undergone bortezomib and lenalidomide treatment (median number of previous treatments: 5), were analyzed. The median time from diagnosis to bendamustine treatment was 3.8 years, and the median patient age was 63 years (range, 38-77 yr). The responses to the last treatment before bendamustine were refractory disease (N=52, 80%) or disease progression from partial response (N=13, 20%). Twenty-three patients responded to the treatment, with an overall response rate of 35% (23/65), and the median number of bendamustine treatment cycles was two (range, 1-5 cycles). The median overall survival after bendamustine treatment was 5.5 months and the overall survival rate in responders to bendamustine was significantly better than that in non-responders (P=0.036). Conclusion Bendamustine may be a potential salvage treatment to extend survival in a select group of heavily pre-treated patients with relapsed or refractory myeloma.

UR - http://www.scopus.com/inward/record.url?scp=84994853809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994853809&partnerID=8YFLogxK

U2 - 10.5045/br.2016.51.3.193

DO - 10.5045/br.2016.51.3.193

M3 - Article

AN - SCOPUS:84994853809

VL - 51

SP - 193

EP - 199

JO - Blood Research

JF - Blood Research

SN - 2287-979X

IS - 3

ER -